An RNA-hydrolyzing recombinant minibody prevents both influenza A virus and coronavirus in co-infection models.

ABSTRACT: With the lifting of COVID-19 non-pharmaceutical interventions, the resurgence of common viral respiratory infections was recorded in several countries worldwide. It facilitates viral co-infection, further burdens the already over-stretched healthcare systems. Racing to find co-infection-associated efficacy therapeutic agents need to be rapidly established. However, it has encountered numerous challenges that necessitate careful investigation. Here, we introduce a potential recombinant minibody-associated treatment, 3D8 single chain variable fragment (scFv), which has been developed as a broad-spectrum antiviral drug that acts via its nucleic acid catalytic and cell penetration abilities. In this research, we demonstrated that 3D8 scFv exerted antiviral activity simultaneously against both

SUBMITTER: Luong QXT 

PROVIDER: S-EPMC11009316 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature